Daxor Corporation Announces Transition To Securities Exchange Act of 1934 Reporting Company, Reaffirming Focus on Core Blood Volume Analysis and Diagnostic Business

Stock Information for Daxor Corporation

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Daxor Corporation

Daxor Corporation to Showcase Next-Generation Portable Blood Volume Analyzer at ACC.26; Highlighting Clinical Outcomes and Reduced Readmissions
Daxor to Debut New Rapid, Portable Blood Volume Analyzer at SCCM 2026 Critical Care Congress
Daxor Corporation to Participate in the iAccess Virtual Alpha Best Ideas Spring Investment Conference 2026
Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders
Daxor Corporation Reports 2025 Fiscal Year Results: Operating Revenue Up 45%, Net Asset Value Rises to $9.07 Per Share
Daxor Scales Outpatient Presence; Launches BVA Diagnostic Program in Tennessee
Daxor Corporation Announces $9 Million Registered Direct Offering
Daxor Fuels Growth with Three New Facility Adoptions and Deployment of Next-Generation BVA Analyzer

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.